T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (2048)	5/22/2003 7:48:24 AM
From: Icebrg	Read Replies (2) of 2243

>>Spectrum Pharmaceuticals (SPPI)>> GPC Biotech gained E0.95 (23%) to E5.15 last week after presenting to investors in Frankfurt. GPC highlighted intentions to report initial Phase II data in June for Satraplatin (at ASCO), an oral platinum chemotherapeutic in-licensed from Spectrum. The presentation which is centered around Satraplatin is available at dvfa.net GPC Biotech continues to sound as if they think that they landed a very good deal on Satraplatin. Let's hope that their optimism will be supported by future events. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next